Company Filing History:
Years Active: 2025
Title: Innovations in Cancer Treatment by Mark DeRose
Introduction
Mark DeRose is an accomplished inventor based in Wilmington, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of multi-specific binding proteins. His work aims to improve therapeutic options for patients suffering from cancer.
Latest Patents
Mark DeRose holds a patent for "Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen." This patent focuses on methods for treating cancer with multi-specific binding proteins that target NKG2D, CD16, and tumor-associated antigens such as HER2. The disclosure includes the use of these proteins in combination with corticosteroids to minimize the risk of infusion-related reactions. Additionally, it covers applications for treating cancers with low or moderate HER2 expression levels, along with pharmaceutical formulations that incorporate these multi-specific binding proteins.
Career Highlights
Mark DeRose is currently associated with Dragonfly Therapeutics, Inc., where he continues to advance his research in cancer therapies. His innovative approach has the potential to transform treatment protocols and improve patient outcomes.
Collaborations
Mark has collaborated with notable colleagues, including Jean-Marie Cuillerot and Christopher Ryan Morgan, to further enhance the development of cancer treatment methodologies.
Conclusion
Mark DeRose's contributions to cancer treatment through his patented methods and collaborative efforts highlight the importance of innovation in medical research. His work exemplifies the potential for advancements in therapeutic strategies that can significantly impact patient care.